Vicus Therapeutics Announces Phase II Data Demonstrating Overall Survival Benefit with VT-122 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

MORRISTOWN, N.J (PRWEB) September 05, 2014 Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, announced positive results from a Phase II randomized, open-label, controlled clinical trial of its lead compound, VT-122, in combination with sorafenib, in patients with advanced hepatocellular carcinoma (HCC). In an intent-to-treat (ITT) population, investigators […]

Latest Literature News

British readers lost in translations as foreign literature sales boom Harvill Secker, a mainstream publisher focused on translated literature, is this year publishing authors from 18 countries including Haruki Murakami and Nesbø, the Norwegian crime writer who has sold more than 23 million copies internationally. Next … Read more on The Guardian Noontime Nuggetz: Literature, […]